Strategic Acquisition Recent merger activity with Aptorum/DiamiR and alignment with Niki BioSolutions signals expanded corporate footprint and potential cross-sell opportunities for diagnostics, contract development, and collaborative research services.

Biomarker Partnerships Jun 2026 collaboration with Alz Labs to analyze blood biomarkers for Alzheimer's presents a pathway to offer assay development, data analytics, and ML-driven biomarker discovery services to accelerate clinical validation.

Clinical Event Footprint Active participation in major conferences such as AAIC demonstrates ongoing thought leadership and opportunities to engage KOLs, prospective clients, and grant-funded projects for blood-based brain health diagnostics.

Software & Ops Readiness Tech stack including WordPress, Shopify, UI frameworks, and API integrations indicates a lean operational model; opportunities exist to streamline client onboarding, regulatory documentation workflows, and e-commerce style discovery for lab services.

Financial Position Sub <$1M revenue with $7.5M funding suggests growth-stage potential; potential to target strategic investors or large CROs for co-development deals, license agreements, or phased funding to scale assays and manufacturing.